DMC recommends Celsion to continue enrollment in ThermoDox clinical study for primary

[News]

Celsion Corporation announced today that after reviewing data from 294 patients including data from 12 Japanese patients enrolled in the pivotal Phase III ThermoDox® clinical study (HEAT Study) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.

More... (http://www.news-medical.net/news/20100514/DMC-recommends-Celsion-to-continue-enrollment-in-ThermoDox-clinical-study-for-primary-liver-cancer.aspx)